Key facts
- It has raised $1.7M across 1 recorded rounds; the latest was Seed Round ($1.7M) in Nov 2022.
- Notable investors include MassBio, Harvard Alumni Entrepreneurs Accelerator.
- PathCision Medicine has filed 1 Form D with the SEC, most recently Feb 2024 ($200K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for PathCision Medicine
Funding rounds
1 roundsAbout PathCision Medicine
Developer of a biotechnology research and development platform designed to create targeted therapies for complex diseases with a focus on metastatic cancers. The company offers a computational pathology-driven discovery platform with enhanced tissue biology insights, proprietary target identification engines, and antibody-drug conjugate development capabilities, enabling healthcare providers and researchers to access precision medicines that address difficult-to-treat cancers and improve treatment prospects.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2022
- Employees
- 6
- Website
- pathcisionmedicine.com/
- Ownership
- Privately Held (backing)
PathCision Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PathCision Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PathCision Medicine in its N-PORT filings yet. We sweep new filings monthly.